Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Acorda Therapeutics (ACOR)
Acorda Therapeutics (ACOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Acorda Therapeutics 2 Blue Hill Plaza 3rd Floor Pearl River NY 10965 USA

www.acorda.com P: 914-347-4300 F: 914-347-4560

Description:

Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA' (dalfampridine) Extended Release Tablets, 10 mg.

Key Statistics

Overview:

Market Capitalization, $K 16,768
Enterprise Value, $K -27,652
Shares Outstanding, K 1,242
Annual Sales, $ 118,570 K
Annual Net Income, $ -65,920 K
Last Quarter Sales, $ 27,720 K
Last Quarter Net Income, $ -8,890 K
EBIT, $ 13,410 K
EBITDA, $ 63,140 K
60-Month Beta 1.44
% of Insider Shareholders 2.60%
Float, K 1,210
% Float 97.40%
Short Volume Ratio 0.01

Growth:

1-Year Return -29.84%
3-Year Return -88.40%
5-Year Return -99.25%
5-Year Revenue Growth -79.84%
5-Year Earnings Growth -153.53%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -7.16 on 11/13/23
Latest Earnings Date 03/14/24
Earnings Per Share ttm -17.11
EPS Growth vs. Prev Qtr 5.17%
EPS Growth vs. Prev Year 37.19%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 06/05/23

ACOR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -21.45%
Return-on-Assets % -4.25%
Profit Margin % -55.60%
Debt/Equity 0.00
Price/Sales 0.15
Price/Cash Flow N/A
Price/Book 0.29
Book Value/Share 47.55
Interest Coverage -0.17
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar